Scientists at Johns Hopkins have uncovered a surprising new way to influence brain activity by targeting a long-mysterious class of proteins linked to anxiety, schizophrenia, and movement disorders.
Rapid neurologic and clinical decline can have a vast differential diagnosis. In this unique case, a man in his mid-70s was found unresponsive at home and progressed to brain death within 36 hours ...
Apathy, social withdrawal, and loss of motivation — the so-called ''negative'' symptoms of schizophrenia — are among the most ...
Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company” or "Solid”), a life sciences company developing precision genetic ...
About the FALCON Trial FALCON is a first-in-human, open-label, multi-center Phase 1b clinical trial designed to evaluate the safety and tolerability of SGT-212 in participants aged 18-40 who have been ...
1 Department of Rehabilitation Medicine, National Hospital Organization Higashisaitama National Hospital, Saitama, Japan 2 Department of Rehabilitation Medicine, Keio University School of Medicine, ...
Phase III trial successfully achieved its primary endpoint and key secondary endpoints with high statistical significance Levacetylleucine demonstrated clinically meaningful improvements in ...
And what to do about it by Thomas Keil and Marianna Zangrillo In their pursuit of strong performance, CEOs and executives often overlook a critical factor in organizational success: the health of ...
Being diagnosed with a serious mental illness like schizophrenia or bipolar disorder often brings an overlooked challenge: rapid and sustained weight gain. This side-effect can raise the risk of ...
Abstract: Fetal cerebellum landmark detection is crucial for assessing fetal brain development. Although deep learning has become the standard for automatic landmark detection, most previous methods ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback